Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2011 Scrip 100: Metabolic/endocrinology trials

This article was originally published in Scrip

Executive Summary

In the metabolic/endocrinology therapeutic area, 245 industry-sponsored Phase II to Phase III trials were initiated between 1 October 2009 and 30 September 2010. 53% of these were Phase III. The leading disease by far was type 2 diabetes, accounting for 46% of total initiated trials and representing more than four-times as many trials as diabetic complications, the second-largest area and the only other metabolic indication with more than 20 trial starts. Of the trials in type 2 diabetes, 61% were Phase III. Fully a quarter of trials in type 2 diabetes examined sodium glucose co-transporter-2 (SGLT-2) inhibitors. This mechanism surpassed either of those targeting the incretin pathway; however, the combination of dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) agonists still accounted for 35% of trials despite regulatory setbacks. Novel insulin analogues accounted for 16% of trial activity, principally from Novo Nordisk. Undefined or newer mechanisms, such as hexokinase activators, interleukin 1b antagonists and GPR119 and GPR40 agonists, were the subject of 24% of trials, mostly Phase II. Notably, cardiovascular safety studies began to appear in response to December 2008 US FDA guidance to evaluate cardiovascular risk for new antidiabetic agents. Cardiovascular outcome studies for seven antidiabetic agents were initiated out of a total of 16 Phase III or recently-approved compounds (apart from insulin analogues) with trial starts during this period. The only other disease with more than 15 trial starts was hyperuricaemia/gout (16 trials), where Novartis's canakinumab in development for gout (also for type 2 diabetes) predominated with six trials.

You may also be interested in...

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts